Phosphodiesterase Type 5 Inhibitors and Risk of Malignant Melanoma: Matched Cohort Study Using Primary Care Data from the UK Clinical Practice Research Datalink.

Matthews, Anthony; Langan, Sinéad M; Douglas, Ian J; Smeeth, Liam; Bhaskaran, Krishnan

Matthews, Anthony; Langan, Sinéad M; Douglas, Ian J; Smeeth, Liam; Bhaskaran, Krishnan.

Afiliação

Matthews A; Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom.
Langan SM; Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom.
Douglas IJ; Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom.
Smeeth L; Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom.
Bhaskaran K; Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom.

PLoS Med ; 13(6): e1002037, 2016 06.

Article em En | MEDLINE | ID: mdl-27299522

Assuntos

Melanoma/epidemiologia; Inibidores da Fosfodiesterase 5/efeitos adversos; Adulto; Idoso; Estudos de Coortes; Humanos; Masculino; Melanoma/induzido quimicamente; Pessoa de Meia-Idade; Fatores de Risco; Reino Unido/epidemiologia; Adulto Jovem

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Inibidores da Fosfodiesterase 5 / Melanoma Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Humans / Male / Middle aged País como assunto: Europa Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google